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PharmacokineticsAbstract The present study was aimed to study the requirements of bioequivalence for the regis-
tration of pharmaceutical products in the USA, Europe and Canada. Before going into bioequiv-
alence studies it is essential for the pharmaceutical industry to study the guidelines of
bioequivalence for the respective country where the industry wants to market its products and thus
enter into generic market. This study reviews the requirements of bioequivalence with study param-
eters such as study design, fasting or fed state studies, volunteers recruitment, study dose, sampling
points, analytical method validation parameters, moieties to be measured in plasma, pharmacoki-
netic parameters, criteria for bioequivalence, GCP requirements etc, which are needed for the phar-
maceutical industry to carry out bioequivalence studies and to ﬁle ANDA. Test products and
reference products are needed for this study. Test products are usually manufactured by a sponsor
and reference products are provided by the government laboratories of the respective countries.
Sampling points also vary with respect to the regulatory guidelines of these countries. All these
countries follow ICH GCP guidelines. The criterion of bioequivalence for these countries is 90%
CI 80–125% for Cmax, AUCt, AUC0–1.
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The concepts of bioavailability (BA) and bioequivalence (BE)
have gained considerable importance during the last three dec-
ades because of their application to new brand-name drugs, as
well as to generic drugs. During this period, regulatory author-
ities also started developing and formulating the regulatory
requirements for the approval of generic drug products. Con-
sequently, tremendous advances have been made in the appli-
cation of assessment approaches to these scientiﬁc concepts.
BA and BE have become the cornerstones for the approval
of brand-name and generic drugs globally and have been uti-lized for brand-name drugs to reduce the cost of development.
It is encouraging to know that there are continuing efforts by
regulatory authorities and the scientiﬁc community, both
nationally and internationally, to understand and develop
more efﬁcient and scientiﬁcally valid approaches to the assess-
ment of BE of various dosage forms including some of the
tough complex special dosage forms. Because of the impor-
tance of generic drugs in healthcare, it is imperative that the
pharmaceutical quality and in vivo performance of generic
drugs be reliably assessed (Midha and McKay, 2009). Because
generic drugs would be interchanged with innovator products
in the market place, it must be demonstrated that the safety
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cacy of the corresponding innovator drugs. Assessment of
‘‘interchangeability’’ between the generic and the innovator
product is carried out by a study of in vivo equivalence or bio-
equivalence (Meredith, 2003).
2. Bioequivalence study requirements for the registration of the
pharmaceutical product in the USA
Requirements of bioequivalence study for the registration of
orally administrated drug products are detailed in 21 CFR
320. (CFR: Code of Federal Regulations) (http://www.access-
data.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?,
2013).
2.1. Experimental design
A randomized, balanced, single-dose, two-treatment (fed vs.
fasting), two period, two sequence crossover design is used
for studying the effects of food on the bioavailability of either
an immediate-release or a modiﬁed release drug product. The
test product and the reference listed drug product should be
administered under fed conditions. An adequate washout per-
iod should separate the two treatments. The formulation to be
tested should be administered on an empty stomach (fasting
condition) in one period and following a test meal (fed condi-
tion) in the other period. A similar, two-treatment, two-period,
two sequence crossover design for a fed bioequivalence study is
often recommended except that the treatment should consist of
both test and reference formulations administered following a
test meal (fed condition). An adequate washout period should
separate the two treatments in food effect bioavailability and
fed bioequivalence studies. For immediate release solid/sus-
pension dosage forms, usually a non-replicate, randomized,
single dose, two treatment, two period, two sequence crossover
design is performed.
2.2. Sample size and dropouts
A minimum number of 12 evaluable subjects should be in-
cluded in any bioequivalence study. When an average bio-
equivalence approach is selected using either non-replicated
or replicated designs, methods appropriate to the study design
should be used to estimate sample sizes. The number of sub-
jects for bioequivalence studies based on either the population
or individual bioequivalence approach can be estimated by
simulation if analytical approaches for estimation are not
available. Sponsors should enter a sufﬁcient number of sub-
jects in the study to allow for dropouts. Because replacement
of subjects during the study could complicate the statistical
model and analysis; dropouts generally should not be replaced.
Sponsors who wish to replace dropouts during the study
should indicate this intention in the protocol. The protocol
should also state whether samples from replacement subjects,
if not used, will be assayed. If the dropout rate is high and
sponsors wish to add more subjects, a modiﬁcation of the sta-
tistical analysis may be recommended. Additional subjects
should not be included after data analysis unless the trial
was designed from the beginning as a sequential or group
sequential design (http://www.accessdata.fda.gov/scripts/
cdrh/cfdocs/cfcfr/CFRSearch.cfm?, 2013).2.3. Food-effect bioavailability and fed bioequivalence studies
Food effect bioavailability studies are usually conducted for
new drugs and drug products during the investigational new
drug (IND) period to assess the effects of food on the rate
and extent of absorption of a drug when the drug product is
administered shortly after a meal (fed conditions), as com-
pared to administration under fasting conditions. Fed bio-
equivalence studies, on the other hand, are conducted for
abbreviated new drug applications (ANDAs) to demonstrate
their bioequivalence to the reference listed drug (RLD) under
fed conditions (Meredith, 2003; http://www.accessda-
ta.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?, 2013).
2.4. Potential mechanisms of food effects on bioavailability
Food can change the BA of a drug and can inﬂuence the BE
between test and reference products. Food effects on BA can
have clinically signiﬁcant consequences. Food can alter BA
by various means, including delay in gastric emptying, stimu-
lation of bile ﬂow, change in gastrointestinal pH, increase of
splanchnic blood ﬂow, change in luminal metabolism of a drug
substance, and physical or chemical interaction with a dosage
form or a drug substance.
2.5. Study considerations
This section provides general considerations for designing food
effect BA and fed BE studies. A sponsor may propose alterna-
tive study designs and data analyses. The scientiﬁc rationale
and justiﬁcation for these study designs and analyses should
be provided in the study protocol. Sponsors may choose to con-
duct additional studies for a better understanding of the drug
product and to provide optimal labeling statements for dosage
and administration (e.g. different meals and different times of
drug intake in relation to meals). In studying modiﬁed-release
dosage forms, consideration should be given to the possibility
that co-administration with food can result in dose dumping,
in which the complete dose may be more rapidly released from
the dosage form than intended, creating a potential safety risk
for the study subjects (http://www.accessdata.fda.gov/scripts/
cdrh/cfdocs/cfcfr/CFRSearch.cfm?, 2013).2.6. Subject selection
Both food-effect BA and fed BE studies can be carried out in
healthy volunteers drawn from the general population of
18 years of age or older and capable of giving informed con-
sent. Studies in the patient population are also appropriate if
safety concerns preclude the enrollment of healthy subjects.
A sufﬁcient number of subjects should complete the study to
achieve adequate power for a statistical assessment.
2.7. Dosage strength
In general, the highest strength of a drug product intended to
be marketed should be tested in food-effect BA and fed BE
studies. In some cases, clinical safety concerns can prevent
the use of the highest strength and warrant the use of lower
strengths of the dosage form. For ANDAs, the same lot and
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fed BE study. For products with multiple strengths in ANDAs,
if a fed BE study has been performed on the highest strength,
BE determination of one or more lower strengths can be
waived based on dissolution proﬁle comparisons.
2.8. Test meal
We recommend that food-effect BA and fed BE studies be con-
ducted using meal conditions that are expected to provide the
greatest effects on GI physiology so that systemic drug avail-
ability is maximally affected. A high-fat (approximately 50%
of total caloric content of the meal) and high-calorie (approx-
imately 800–1000 calories) meal is recommended as a test meal
for food-effect BA and fed BE studies. This test meal should
derive approximately 150, 250, and 500–600 calories from pro-
tein, carbohydrate, and fat, respectively. The caloric break-
down of the test meal should be provided in the study
report. If the caloric breakdown of the meal is signiﬁcantly dif-
ferent from the one described above, the sponsor should pro-
vide a scientiﬁc rationale for this difference. In new drug
applications (NDAs), it is recognized that a sponsor can
choose to conduct food effect BA studies using meals with dif-
ferent combinations of fats, carbohydrates, and proteins for
exploratory or label purposes. However, one of the meals for
the food-effect BA studies should be the high-fat, high-calorie
test meal described above.
2.9. Administration
2.9.1. Fasted treatments
Following an overnight fast of at least 10 h, subjects should be
administered the drug product with 240 mL (8 ﬂuid ounces) of
water. No food should be allowed for at least 4 h post-dose.
Water can be allowed as desired except for one hour before
and after drug administration. Subjects should receive stan-
dardized meals scheduled at the same time in each period of
the study.
2.9.2. Fed treatments
Following an overnight fast of at least 10 h, subjects should
start the recommended meal 30 min prior to administration
of the drug product. Study subjects should eat this meal
in 30 min or less; however, the drug product should be
administered 30 min after the start of the meal. The drug
product should be administered with 240 mL (8 ﬂuid ounces)
of water. No food should be allowed for at least 4 h post-
dose. Water can be allowed as desired except for one hour
before and after drug administration. Subjects should receive
standardized meals scheduled at the same time in each per-
iod of the study.
2.10. Sample collection
For both fasted and fed treatment periods, timed samples in
the biological ﬂuid, usually plasma should be collected from
the subjects to permit characterization of the complete shape
of the plasma concentration–time proﬁle for the parent drug.
It may be advisable to measure other moieties in the plasma,
such as active metabolites, and sponsors should refer to theguidance on bioavailability and bioequivalence studies for or-
ally administered drug products and general considerations for
recommendations on these issues. Consideration should be gi-
ven to the possibility that co-administration of a dosage form
with food can alter the time course of plasma drug concentra-
tions so that fasted and fed treatments can have different sam-
ple collection times.
If the pre-dose concentration is 65% of Cmax value in that
subject, the subject’s data without any adjustments can be in-
cluded in all pharmacokinetic measurements and calculations.
It is recommend that if the pre-dose value is greater than 5%
of Cmax, the subject be dropped from all bioequivalence study
evaluations. The subjects who experience emesis during the
course of a bioequivalence study for immediate-release prod-
ucts are deleted from statistical analysis if vomiting occurs at
or before two times median Tmax. In the case of modiﬁed-re-
lease products, the data from subjects who experience emesis
any time during the labeled dosing interval can be deleted
(Grabowski et al., 2012).
2.11. Moieties to be measured
The moieties to be measured in biological ﬂuid collected in bio-
equivalence studies are either the active drug ingredient or its
active moiety in the administered dosage form (parent drug)
and, when appropriate, its active metabolite(s). This guidance
recommends the following approaches for bioequivalence
studies: Measurement of only the parent drug released from
dosage form, rather than the metabolite, is generally recom-
mended. The rationale from this recommendation is that the
concentration–time proﬁle of the parent drug is more sensitive
to changes in formulation performance than a metabolite,
which is more reﬂective of metabolite formation, distribution,
and elimination.2.12. Collection of biological matrix and sampling schedule
Several samples of appropriate biological matrix (blood,
plasma/serum, and urine) are collected at various time inter-
vals post-dose. The sampling schedule depends on the phar-
macokinetic characteristics of the drug tested. In most cases,
plasma or serum is the matrix of choice. However, if the
parent drug is not metabolized and is largely excreted un-
changed and can be suitably assayed in the urine, urinary
drug levels may be used to assess bioequivalence, if plasma/
serum concentrations of the drug cannot be reliably mea-
sured. Sufﬁcient numbers of samples are collected during
the absorption phase to adequately deﬁne the ascending por-
tion of the plasma drug level versus time curve. Intensive
sampling is carried out around the time of the expected peak
concentration. Sufﬁcient numbers of samples should also be
collected in the log–linear elimination phase of the drug so
that the terminal elimination rate constant and half-life of
the drug can be accurately determined. A sampling period
extending to at least four to ﬁve terminal elimination half-
lives of the drug or four to ﬁve of the longest half-live of
the pertinent analyte (if more than one analyte) is usually
sufﬁcient. The samples are appropriately processed and
stored carefully under conditions that preserve the integrity
of the analyte(s) (Grabowski et al., 2012).
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pharmaceutical product in Europe
The design should be based on a reasonable knowledge of the
pharmacodynamics and/or the pharmacokinetics of the active
substance in question. For the pharmacokinetic basis of these
studies reference is made to the recommendation ‘‘Pharmaco-
kinetic studies in man’’. The design and conduct of the study
should follow European-regulations on Good Clinical Prac-
tice, including reference to an Ethics Committee.
3.1. Design
The study should be designed in such a way that the formula-
tion effect can be distinguished from other effects. If the num-
ber of formulations to be compared is two, a two-period, two-
sequence crossover design is often considered to be the design
of choice. However, under certain circumstances and provided
the study design and the statistical analyses are scientiﬁcally
sound alternative well-established designs could be considered
such as parallel design for very long half-life substances and
replicate designs for substances with highly variable disposi-
tion (Garcia-Arieta et al., 2012).
3.2. Subjects
3.2.1. Number of subjects
The number of subjects to be included in the study should be
based on an appropriate sample size calculation. The mini-
mum number of subjects in a cross-over study should be 12.
3.2.2. Selection of subjects
The subject population for bioequivalence studies should be
selected with the aim to permit detection of differences be-
tween pharmaceutical products. In order to reduce variability
not related to differences between products, the studies should
normally be performed in healthy volunteers unless the drug
carries safety concerns that make this unethical. This model,
in vivo healthy volunteers, is regarded adequate in most in-
stances to detect formulation differences and the results will al-
low extrapolation to populations in which the reference
product is approved (the elderly, children, patients with renal
or liver impairment, etc.). The inclusion/exclusion criteria
should be clearly stated in the protocol. In general, subjects
should preferably be between 18–55 years old and of weight
within the normal range according to accepted normal values
for the body mass index.
3.3. Study conduct
3.3.1. Standardization
The test conditions should be standardized in order to mini-
mize the variability of all factors involved except that of the
products being tested. Therefore, it is recommended to stan-
dardize diet, ﬂuid intake and exercise. The time of day for
ingestion should be speciﬁed. As ﬂuid intake may inﬂuence
gastric passage for oral administration forms, the test and ref-
erence products should be administered with a standardized
volume of ﬂuid (at least 150 mL). All meals and ﬂuids
(257 mL) taken after the treatment should also be standardizedin regard to composition and time of administration during the
sampling period.
3.3.2. Sampling times
A sufﬁcient number of samples to adequately describe the
complete plasma concentration–time proﬁle should be col-
lected. The sampling schedule should include frequent sam-
pling around Cmax to provide a reliable estimate of peak
exposure. The sampling schedule should be planned to avoid
Cmax being the ﬁrst point of a concentration time curve.
When partial AUC is to be determined, frequent early sam-
pling is recommended with preferably at least two quantiﬁ-
able samples before expected Tmax. The sampling schedule
should also cover the plasma concentration time curve long
enough to provide a reliable estimate of the extent of expo-
sure which is achieved if AUCt is at least 80% of AUC1.
At least three to four samples are needed during the termi-
nal log–linear phase in order to reliably estimate the termi-
nal rate constant (which is needed for a reliable estimate of
AUC1). A sampling period longer than 72 h is not consid-
ered necessary for any immediate release formulation.
Hence, for drugs with a long half-life, comparison of extent
of exposure using truncated AUCs at 72 h is acceptable
(Garcia-Arieta et al., 2012; Schellekens et al., 2011).
3.3.3. Fasting or fed conditions
In cases where information is required in both the fed and
fasted states, it is preferable to conduct a four-period single
dose crossover design study (both products fed and fasted)
rather than conducting two separate bioequivalence studies
in fed and fasted states, respectively. In a four-period crossover
design study, the food effect on test and reference products can
be evaluated which is not the case when conducting two sepa-
rate two-period, two-sequence single dose crossover design
studies under fasting and fed conditions, respectively. In addi-
tion to the bioequivalence evaluation of test/reference in fast-
ing and in fed state, the food effect can be presented for test
and reference, i.e. the ratio food/fasting and 90% conﬁdence
interval for test and reference, respectively. The meal should
be a ‘‘standardized non high-fat meal’’ (about 650 kcal with
about 30% of calories derived from fat). The composition of
the meal should be described with regard to protein, carbohy-
drate and fat content (speciﬁed in grams, calories and relative
caloric content (%).
3.4. Reference and test product
Test products in an application for a generic product are nor-
mally compared with the corresponding dosage form of an
innovator medicinal product (reference product). The choice
of reference product should be justiﬁed by the applicant. For
an abridged application claiming essential similarity to a refer-
ence product, application to numerous associate countries
based on bioequivalence with a reference product from one
associate country can be made. Such an application can be
considered acceptable unless there is a signiﬁcant difference be-
tween the reference products originating from the same manu-
facturer (or its subsidiaries/licensees), in terms of the
qualitative and quantitative composition in excipients. Con-
cerned associate countries may request information from the
ﬁrst associate country on the reference product, namely on
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speciﬁcation (Schellekens et al., 2011).
4. Bioequivalence study requirements for registration of
pharmaceutical product in Canada
Selection of subjects for a study
A certain minimum number of subjects should be used,
and, if a subject withdraws or must be removed from the study,
then an explanation for the withdrawal or removal must be in-
cluded in the study documentation.
4.1. Choice of subjects
Drugs with uncomplicated characteristics can usually be tested
in normal, healthy volunteers. The investigators should ensure
that female volunteers are not pregnant or likely to become
pregnant during the study. Conﬁrmation should be obtained
by urine tests just before the ﬁrst and last doses of the study.
In some instances, studies may be required to ascertain bio-
availability in patients or subjects with special characteristics
– for example, for drugs to be used in the treatment of condi-
tions accompanied by altered absorption or distribution, or for
drugs to be used in special age groups such as children or the
elderly (Shram, 2012).
4.2. Considerations in subject characteristics
An important objective in the selection of subjects is to reduce
the intra-subject variability in pharmacokinetics that may be
attributable to certain characteristics of the subject. Subjects
should be assigned in such a way that the study design is bal-
anced for any factors that are suspected to contribute to
variability.
4.2.1. Age
Subjects should be between the age of legal majority and the
age of onset of age associated changes in organic function.
This description typically coincides with an age range of 18–
55 years, inclusive.
4.2.2. Height/weight ratio
The ratio for healthy volunteer subjects should be within 15%
of the normal range – for example, as given in current Ciba-
Geigy or Metropolitan Life Insurance tables.4.2.3. Health
The health of the volunteers must be determined by the super-
vising physician through a medical examination and review of
results of routine tests of liver, kidney, and hematological func-
tions. An electrocardiogram should be included in the study
documentation if the drug has a cardiac effect. Aberrant labo-
ratory values should be rechecked and a summary must be pre-
sented along with the physician’s opinion. Psychological
characteristics should also be assessed by the physician in or-
der to exclude patients unlikely to comply with study restric-
tions or unlikely to complete the study. Subjects who have
been previously treated for gastrointestinal problems (such as
ulcers), or convulsive, depressive, or hepatic disorders, and inwhom there is a risk of a recurrence during the study period,
should be excluded.
4.3. Number of subjects
The number of subjects to be used in the cross-over study
should be estimated by considering the standards that must
be passed and the drug products being compared. The proba-
bility that a study of a given size will pass the standards de-
pends on the expected mean difference between the test and
reference formulations of both AUCt and Cmax, and the antic-
ipated intra-subject coefﬁcient of variation (CV) of both AUCt
and Cmax. For drugs with uncomplicated characteristics, the
intra-subject CV is generally less than 20%; however, as a re-
sult of sampling, or if the study is poorly run, the intra-subject
CV can be higher. The minimum number of subjects is 12, but
a larger number is often required (Shram, 2012).
4.4. Drop-outs and withdrawal of subjects from a study
The subjects must be available, without compulsion, for all
legs of the study. It is recommended that the number of sub-
jects should be sufﬁcient to allow for possible drop-outs or
withdrawals. Reasons for withdrawal (e.g., adverse drug reac-
tion) must be reported and the subject’s plasma (or blood, or
serum) level data provided. The results of all samples that were
measured in subjects who were withdrawn from the study must
be included in the report. If subjects drop out of the study for
personal reasons, the subject’s blood samples do not have to be
assayed. Reimbursement policy should be speciﬁed prior to
initiating the study and should be in agreement with medical
research council (MRC) or similar guidelines.
4.5. Study design and environment
The design of a bioavailability study should minimize variabil-
ity that is not attributable to the drug per se and should elim-
inate bias as much as possible. The guidance in this section
serves for the usual case. Other designs may be permissible
after consultation with Health Canada (HC) before the study
is initiated. The basic design to be used is a two-period
cross-over, in which each subject is given the test and reference
formulations. In cases where more than two formulations are
under study, or are studied under different conditions, each
volunteer should receive all treatments in a restricted random-
ized design. However, when the number of treatments result in
a study that is longer than a month, a balanced incomplete
block design may be considered.
4.6. Standardization
Every effort should be made to standardize the study condi-
tions in every phase of the study – for example, exercise, diet,
smoking, and alcohol use. It is preferable to use non-smokers;
where smokers are included, they must be so identiﬁed. Volun-
teers should not take any other drug, including alcoholic bev-
erages and over-the counter (OTC) drugs, for an appropriate
interval before-as well as during-the study. In the event of
emergency, the use of any drug must be reported (dose and
time of administration). The decision whether to include or
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established protocol should be made before statistical analysis
commences (Shram, 2012; Daley-Yates al., 2009).
4.7. Blinding
If possible, the study should be conducted in such a way that
the subject is not aware of which product is administered. Fur-
thermore, the person checking for adverse reactions and the
person conducting the analysis of samples must not know
which product was administered. Other individuals involved
in the administration of the drugs, the surveillance of the pa-
tients, or the analysis of plasma (or blood, or serum) data
should not know which product was administered.
4.8. Administration of food and ﬂuid
The administration of food and ﬂuid should be controlled care-
fully.Normally, subjects should fast for 10 h before drug admin-
istration. A fast means that no food or solids are to be
consumed, although alcohol-free and xanthine-free clear ﬂuids
are permissible the night prior to the study. On the morning of
the study, up to 250 mL of water may be permitted up to two
hours before drug administration. The dose should be taken
withwater of a standard volume (e.g., 150 mL) and at a standard
temperature. Two hours after drug administration, 250 mL of
xanthine-free ﬂuids are permitted. Four hours after drug admin-
istration, a standard meal may be taken. All meals should be
standardized and repeated on each study day. If the oral prepa-
ration is being comparedwith an intravenous (IV) dose, the food
and ﬂuid restrictions noted above should also apply to the IV
dose. Some drugs are given with food to reduce gastrointestinal
side effects. Studies of such drugs should include studies with
standard meals. The nature of the test meal to be administered
in the part of the studywhere the formulation is given in the pres-
ence of food-should be determined based on the physicochemi-
cal and pharmacokinetic characteristics of the drug and its
formulation. The purpose is to select a test meal that has the
greatest potential to demonstrate altered bioavailability. The
meal should be given within a predetermined, constant time of
administration of the drug. The appropriate choice of themeal’s
timing and its contents should be chosen carefully.
4.9. Sampling times
The duration of blood or urine sampling in a study should be
sufﬁcient to account for at least 80% of the known area under
curve (AUC) to area under curve to inﬁnity (AUC1). This per-
iod is usually at least three times the terminal half-life of the
drug. To permit calculation of the relevant pharmacokinetic
parameters, from 12 to 18 samples should be collected per sub-
ject per dose. An account of inter-subject variability should be
used in the placement and number of samples. The exact times
at which the samples are taken must be recorded and spaced
such that the following information can be estimated accu-
rately (Walker, 2006).
4.10. Sampling of blood or urine
Under normal circumstances, blood should be the biological
ﬂuid sampled to measure the concentrations of the drug. Inmost cases the drug may be measured in serum or plasma;
however, in some cases, whole blood may be more appropriate
for analysis. If the concentrations in the blood are too minute
to be detected and a substantial amount (>40%) of the drug is
eliminated unchanged in the urine, then the urine may serve as
the biological ﬂuid to be sampled. When urine is collected at
the study center, the volume of each sample must be measured
immediately after collection and included in the report. Urine
should be collected over no less than three times the terminal
elimination half-life. For a 24 h study, sampling times of 0–2,
2–4, 4–8, 8–12, and 12–24 h are usually appropriate. Quantita-
tive creatinine determinations of each urine sample are also re-
quired. Sometimes the concentration of drug in a ﬂuid other
than blood or urine may correlate better with effect. Neverthe-
less, the drug must ﬁrst be absorbed prior to distribution to the
other ﬂuids such as the cerebrospinal ﬂuid, bronchial secre-
tions, and so on. Thus, for bioavailability estimations, blood
is still to be sampled and assayed (Walker, 2006).
4.11. Test and reference drug products
Drug and reference materials must be of high quality and men-
tion must be made in the study documentation (report) of the
dosage and strength of the drug and what reference product is
used in the study. In bioequivalence studies, the molar equiva-
lent dose of each product should be used. The lots for compar-
ative bioavailability testing should be taken from a batch that
is comparable in size and is produced using the same type of
equipment and procedures proposed for the market. In other
words, the lots for comparative bioavailability testing should
be representative of proposed production batches. For an
uncomplicated drug in which the proportions of excipients to
the drug and the dissolution characteristics are the same, it is
sufﬁcient to establish the bioavailability of one strength.
Whether all strengths of other products should be tested will
depend on the extent to which the formulation differs among
strengths. For some of the complicated drugs-such as those
with narrow therapeutic ranges, steep dose–response charac-
teristics, or with non-linear kinetics that would inﬂuence a sin-
gle-dose study, the bioavailability of each strength of the drug
should be established.
4.11.1. Selection of reference product
For a new drug substance (i.e., the ﬁrst market entry), an oral
solution should be used as the reference product when possi-
ble. The oral solution can be prepared from an intravenous
solution, if available. In bioequivalence studies, the reference
product is a drug product that has been issued a notice of com-
pliance pursuant to section C.08.004 of the Food and Drug
Regulations, and is currently marketed in Canada by the inno-
vator, a drug product acceptable by the director. Table 1 in-
cludes documents required to ﬁle ANDA and Table 2
contains contents to be considered while preparing protocol
synopsis.
5. Format and content of the report on bioequivalence studies to
be submitted
The report of a bioequivalence study should give the complete
documentation of its protocol, conduct and evaluation com-
plying with the declaration of Helsinki and Good Clinical
Table 1 Document requirements to ﬁle ANDA.
Title page 1. Study title
2. Name of sponsor
3. Name and address of the sites where the clinical and analytical aspects
of the studies were carried out
4. Name, address of the investigator(s)
5. Name, address of the clinical investigator(s)
Table of contents
(I) Study resume 1. Name, and signature of the investigator(s)
2. Name, and signature of the clinical investigator(s)
3. Products’ information including names and batch numbers of the
reference and test products compared and the source of the reference product
4. Summary of bioequivalence study
5. Summary of bioequivalence data
6. Figure of mean plasma concentration–time proﬁle
7. Figure of mean cumulative urinary excretion
8. Figure of mean urinary excretion rates
(II) Clinical study 9. Introduction
10. Summary of the study
11. Details of the study
12. Demographic characteristics of the subjects
13. Subject assignment in the study
14. Details of clinical activity
15. Details of a justiﬁcation for, any deviations from the protocol, drop-outs,
withdrawal from the study
16. Form for theoretical sampling frequency and actual sampling times
17. Adverse reactions report
(III) Assay methodology and validation 18. Assay method description
19. Validation procedure
20. Summary of validation
21. Data on linearity of standard samples
22. Data on inter-day precision and accuracy
23. Data on analyte(s) stability
24. Figure for standard curve(s) for low/high ranges
25. Representative chromatograms demonstrating the speciﬁcity and sensitivity
of the assay including chromatograms of LLOQ and blanks (Copies of all the
chromatograms should not be included but must be available to be supplied
upon request)
26. Sample calculation
(IV) Pharmacokinetic parameters 27. Deﬁnition and calculations of the pharmacokinetic parameters
28. Individual and average pharmacokinetic parameters
29. Drug levels at each sampling time and pharmacokinetic parameters
30. Figure of mean plasma concentration–time proﬁle (presented as both
linear–linear and log–linear graphs)
31. Figures of individual subject plasma concentration–time proﬁles
(presented as both linear–linear and log–linear graphs)
32. Figure of mean accumulative urinary excretion
33. Figures of individual subject cumulative urinary excretion
34. Figure of mean urinary excretion rates
35. Figures of individual subject urinary excretion rates
36. Tables of individual subject data arranged by drug, drug/period, drug/sequence
(V) Statistical analyses 37. Details and results of statistical analysis
38. Summary of statistical signiﬁcance
39. Summary of statistical parameters
40. Analysis of variance
41. Parametric and/or nonparametric 90% conﬁdence intervals (lower limit,
upper limit and point estimate)
42. Two one-sided t-tests (lower limits, upper limits of the calculated test
statistics and the tabulated t-value)
(VI) Protocol including the criteria for inclusion, exclusion or removal of subjects
(VII) Informed consent
(VIII) Appendices 43. Randomization schedule
44. Analytical raw data
45. Medical record and clinical reports
(IX) In vitro testing 46. Dissolution testing
47. Dissolution assay methodology
48. Content uniformity testing
49. Potency determination
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Table 2 Considerations for preparing protocol synopsis (Chen, 2011).
Contents Description required
Trial title and protocol number/code Provide the title and protocol number/code of the trial. The version number of the protocol should also be provided
Background and rationale A brief, concise introduction into the clinical problem and previous treatments and developments, i.e., pertinent data from previous
preclinical/clinical pharmacology studies and therapeutic exploratory studies. Information on the new drug. Reasoning and justiﬁcation
for the proposed new approach
Trial objectives Statement of the precise goal(s) of the trial (may be subdivided into primary and secondary objectives) which may including testing of the
null hypothesis (Ho), i.e., testing a new drug population/ indication etc., as applicable
Study design and duration 1. The statement of study design should include the method of randomization, blinding and the comparative agent, if applicable
2. A ‘‘Brief outline of the study conduct’’ should be included, if applicable
3. The design of the study should be able to support any claims related to the proposed study
4Total study duration (anticipated starting/ﬁnishing dates)
5. Duration for each subject including post treatment period etc.
Sample size Rationale and calculation for sample size requirement, anticipated drop-out rate etc. The sample determination may include Ho testing
and desired power of the study.
Patient population Description of speciﬁc characteristics of the trial participants (e.g. diseases/stage/indication/condition/treatment etc.) as applicable and of
diagnostic criteria and assessment
Inclusion and exclusion criteria Enumeration of conditions determining participation in the proposed clinical trial
Drug formulation Brief description of the study drug(s) and formulation to be used in the clinical trial also include disclosure of the formulation intended to
be marketed and/or any bridging studies which may be necessary, planned, initiated and/or already performed if diﬀerent formulations
have been used during clinical development
Dosage regimen Rationale for dose selection. Description of the schedule(s) for using the study drug(s) including escalations/maintenance/reductions/discontinuation,
as applicable. Description of other supportive measures and dose modiﬁcations for speciﬁc adverse events (anticipated toxicities), as applicable
Washout Period Description for pre-dose, during and post-trial, as applicable
Pre-study screening and baseline evaluation Description of the process of clinical validation for participation in the clinical trial, including methodology/schedule of events
Treatment/assessment visits Schedule of all events/visits/procedures during the clinical trial
Concomitant medication Enumeration and description of all disallowed/allowed drug/medications, in addition to the study drugs
Rescue medication and risk management Description of available supportive measures/antidotes/medications/dosages/procedures (including follow-up) used to help reverse untoward eﬀects
or lack of eﬃcacy resulting from any applications of drug(s)/procedures in connection with the clinical trial. This should include any risks,
for example,
dose dumping from slow release formulations or immunogenicity
Premature withdrawal/discontinuation criteria Enumeration of all conditions/criteria and management for drug/patient’s withdrawal or Premature discontinuation, including voluntary
withdrawal by subject without prejudice to future treatment by the physician
Eﬃcacy Variables and Analysis Description and validation of primary endpoint(s), i.e. responses/changes from baseline over time in relation to clinical trial events.
Description and validation of related secondary endpoint(s) following from clinical trial events
Safety variables and analysis Monitoring/assessing adverse drug reactions/adverse events/toxicities/clinical laboratory parameters etc. In relation to clinical trial events
Statistical analysis 1. Analysis of trial parameters (primary/secondary endpoints), population, demographics, as applicable
2. Eﬃcacy analysis methods and results of eﬃcacy end-point analysis
3. Safety analysis methods and results of safety end-point analysis
4. Exploratory end-point analysis: evaluation eﬀect(s) (or lack of eﬀects) of relevant biochemical/pharmacological etc. Parameters, as applicable
5. Pharmacokinetic endpoint analysis, as applicable. interim analysis and role of data safety monitoring board, as applicable
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Table 3 Comparative assessment of study parameters between USA, Europe and Canada (Borgherini, 2003; Nation, 1994; Galgatte et al., 2013).
Sr. no. Parameters USA Europe Canada
1 Study design Non-replicated, randomized, crossover
studies
Non-replicated, randomized, crossover
studies
Non-replicated, randomized, crossover
studies
2 Fasting/fed state studies Fasting and fed Fasting Fasting
3 Volunteers Suﬃcient to achieve adequate power >12 (Min 80% power of acceptance
criteria)
Min 80% power of acceptance criteria
4 Study dose Test Made by the manufacturer Made by the manufacturer Made by the manufacturer
Reference Reference listed drug in USA European reference product Canadian reference product
5 Sampling points 12–18 samples, more samples should
be collected at Tmax, to be continued up
to 3 or more half lives
At least 2 samples before expected Tmax,
3–4 terminal log–linear phase
12–18 samples per subject/dose
6 Analytical method validation
parameters
Accuracy, precision, selectivity, sensitivity,
reproducibility, calibration curve, LLOQ
and stability
Accuracy, precision, repeatability,
intermediate precision speciﬁcity,
detection. limit of quantitation,
linearity range
Stability, L.O.Q, speciﬁcity, recovery,
standard curves, precision and accuracy
7 Moieties to be measured in plasma Active drug/metabolites if applicable Active drug/metabolites if applicable Active drug/metabolites if applicable
8 Pharmacokinetic parameters Cmax, Tmax, AUC0–t and AUC0–1, t1/2, kz Cmax, Tmax, AUC0–t and AUC0–1, t1/2, kz Cmax, Tmax, AUC0–t and AUC0–1, t1/2, kz
9 Criteria for bioequivalence 90% CI 80.00–125.00% for Cmax, AUCt,
AUC0–1
90% CI 80.00–125.00 for Cmax, AUCt,
AUC0–1 (for highly variable drugs
75–133%)
90% CI 80–125% for Cmax, AUCt, AUC0–1
10 GCP requirements ICH GCP guidelines ICH GCP guidelines ICH GCP guidelines
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pendent ethics committee or institutional review board. The
responsible investigator(s) should sign for their respective
section of the report. Name and afﬁliations of the responsi-
ble investigator(s), site of the study and period of its execu-
tion should be stated. The names and batch numbers of the
pharmaceutical products used in the study as well as the
composition(s) of the test product should be given. The ana-
lytical validation report should be attached. Results of
in vitro dissolution tests should be provided. In addition,
the applicant should submit a signed statement conﬁrming
the identity of the test product with the pharmaceutical
product, which is submitted for registration. All results
should be presented clearly. The procedure for calculating
the parameters used (e.g., AUC) from the raw data should
be stated. Deletion of data should be justiﬁed. If results
are calculated using a pharmacokinetic model (although
not preferred), the model and computing procedure used
should be justiﬁed. Individual plasma concentration/time
curves should be drawn on a linear/linear scale. All individ-
ual data and results should be given, including those of
eventually dropped-out subjects. Drop-out and withdrawal
of subjects should be reported and accounted for. Test re-
sults of representative samples should be included. The sta-
tistical report should be sufﬁciently detailed, so as to enable
the statistical analyses to be repeated if necessary. If the sta-
tistical methods applied deviate from those speciﬁed in the
trial protocol, the reasons for the deviations should be sta-
ted. The following is a proposed format and contents of
an in vivo bioequivalence study submission and accompany-
ing in vitro data (Mugglestone, 2012) (Table 3).5.1. United States
The FDA considers two products bioequivalent if the 90% CI
of the relative mean Cmax, AUC0–t and AUC0–1 of the test
(e.g. generic formulation) to reference (e.g. innovator brand
formulation) should be within 80.00–125.00% in the fasting
state. Although there are a few exceptions, generally a bio-
equivalent comparison of Test to Reference formulations also
requires administration after an appropriate meal at a speciﬁed
time before taking the drug, a so called ‘‘fed’’ or ‘‘food-effect’’
study. A food-effect study requires the same statistical evalua-
tion as the fasting study.
5.2. Europe
According to European regulations, European medicines
agency (EMEA-CPMP), Note for guidance on the investiga-
tion of bioavailability and bioequivalence, London, July
2001 CPMP/EWP/QWP/1401/98 two medicinal products are
bioequivalent if they are pharmaceutically equivalent or phar-
maceutical alternatives and if their bioavailability after admin-
istration in the same molar dose are similar to such a degree
that their effects, with respect to both efﬁcacy and safety, will
be essentially the same. This is considered demonstrated if the
90% conﬁdence intervals (90% CI) of the transformed natural
log ratios, between the two preparations, of Cmax and AUC lie
in the range of 0.80–1.25.5.3. Canada
Health Products and Food Branch guidance document pro-
vides information about how to establish and conduct bio-
equivalence studies for conventional formulations of oral
drugs that are used for systemic effects. This guidance takes
into account a variety of physicochemical, pharmacokinetic,
and clinical characteristics of different drugs and drug prod-
ucts, in addition to the availability of methods for measuring
a drug and its metabolites. The 90% conﬁdence interval of
the relative mean AUCt and Cmax of the test to reference prod-
uct should be within 80–125%.
6. Conclusion
Comprehensive assessment of study parameters between USA,
Europe and Canada revealed that these three countries follow
ICH GCP guidelines. Moieties to be measured in plasma phar-
macokinetic parameters and criteria for bioequivalence are the
same. Due to harmonization of regulatory requirements for
bioequivalence studies, major changes in policies and proce-
dures concerning the determination of bioavailability and bio-
equivalence took place. Therefore in the near future one may
expect appropriate choice of a clinically relevant bioequiva-
lence range based on therapeutic ranges, absorption proﬁle
and ultimately experimental design to resolve the issue of intra
and inter subject variability.
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